In a study commissioned by EUCOPE, the Office of Health Economics (OHE) assessed the extent to which the Orphan Medicinal Products (OMPs) Regulation (2000/018) has successfully incentivised companies to invest in research and development of OMPs. The study also puts forward an analysis of the… read more
EUCOPE asks the European Commission to put research at the heart of its Pharmaceutical Strategy The European Commission’s Pharmaceutical Strategy for Europe must: Provide ambitious measures to foster research in rare diseases and other disease areas for which we currently have no cure. Harness the… read more
On Rare Diseases Day, EUCOPE is delighted to host an interview with Laurence Woollard, patient expert and rare disease advocate, to discuss with him the importance of an engaged community and the opportunities and challenges new treatments can bring. See Laurence’s Q&A on our blog.
On the 3rd of March, in Paris, France, the Rare Diseases Research (RDR) initiative will organise a networking event for SMEs, academia and interested stakeholders to take part in research project targeting specific rare diseases challenges. Within the framework of the European Joint Programme on… read more
The Czech Ministry of Health recently announced that the Public Health Insurance Act 48/1997, which regulates the scope and conditions under which health services are covered as well as their pricing and reimbursement, would be amended. The foreseen amendments, expected to enter into force in… read more
The nominations for the EURORDIS Black Pearl Awards 2020 are now open until 13 September 2019! The Black Pearl Awards is an annual event organised by EURORDIS, the alliance of more than 800 rare disease patient organisations, to recognise the outstanding achievements and exceptional work… read more
On 17 June 2019, the EU Commission (EC) will gather a large spectrum of stakeholders from the Member States, patients, academia, healthcare professionals and industry to collect their views on the successes and limitations of the regulatory framework for Paediatric medicines and Orphan Medicinal Products… read more